It has been reported that TTFields can reduce glioblastoma cell proliferation and increase apoptosis in combination with chemosuppression of SAC, with the potential as a bridge to clinical disruption of TTFields therapy (46). The gene discussed is ADCY10; the disease is glioblastoma.